Tricyclic Antidepressants and MAOIs

A high-level examination of the first-generation antidepressants — their receptors, mechanisms, enduring value, and the reasons they were displaced but not surpassed

What These Drugs Are, and Why They Still Matter

The tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) are the first-generation antidepressants — the drugs that, in the 1950s, established that depression was pharmacologically treatable and that, in the process, generated the monoamine hypothesis that dominated psychiatry for half a century. They were displaced from first-line use by the SSRIs not because they were less effective — by several measures they are equally or more effective — but because they were more dangerous and less tolerable, and because a safer, easier class made mass primary-care and long-term prescribing feasible. This distinction is the central fact about them and the recurring theme of this document: the first-generation antidepressants were superseded on safety and tolerability, not on efficacy, and understanding them corrects the common misimpression that newer means better.

They matter today for three reasons. First, clinically: both classes retain genuine, sometimes irreplaceable roles — TCAs for certain pain syndromes, severe/melancholic and treatment-resistant depression, OCD (clomipramine), and other niches; MAOIs as arguably the most effective option for atypical and treatment-resistant depression in expert hands. Second, historically and conceptually: their accidental discovery created the monoamine hypothesis, and their broad, "dirty" pharmacology illuminates by contrast what the SSRIs' selectivity bought and cost. Third, as a cautionary corrective: the story of two highly effective classes pushed to the margins by interaction-management and overdose-safety concerns is a lesson in how non-efficacy factors — tolerability, safety, marketing, prescribing convenience — shape what patients actually receive, a theme running throughout this pharmacology series (lithium and clozapine are the parallel cases).

The honest framing: these are powerful, effective, underused drugs with serious safety burdens that justified their demotion from routine use but not their near-abandonment — and a careful psychiatry keeps them available, and keeps the expertise to use them, for the patients the newer drugs fail.

The Accidental Discovery and the Monoamine Hypothesis

Both classes were discovered by accident in the 1950s, and the accident built modern biological psychiatry.

The MAOIs came first, from tuberculosis. Iproniazid, an antitubercular drug, was noticed in the early 1950s to elevate the mood of TB patients — making them euphoric, energized, "dancing in the wards." Investigation revealed it inhibited monoamine oxidase, the enzyme that degrades serotonin, norepinephrine, and dopamine — so the mood elevation was attributed to raised monoamine levels. The first antidepressant class was thus born from an antibiotic's side effect.

The TCAs came from antipsychotic research. Imipramine, synthesized as a chlorpromazine-like compound and tested (by Roland Kuhn, 1957) as a potential antipsychotic, failed to help psychosis but unexpectedly lifted depression — and was found to block the reuptake of norepinephrine and serotonin, raising their synaptic levels.

The hypothesis. These two convergent observations — that drugs raising monoamines (by inhibiting their breakdown, or by blocking their reuptake) treat depression, while reserpine (which depletes monoamines) causes depression — produced the monoamine hypothesis of depression: that depression results from a deficiency of monoamine neurotransmitters, and antidepressants work by correcting it. This hypothesis dominated psychiatry for fifty years, drove the development of every subsequent antidepressant (the SSRIs were rational attempts to do selectively what the TCAs did messily), and has since substantially collapsed as an etiological theory, even as the drugs it spawned remain useful. The first-generation antidepressants are thus the source of both the field's central organizing idea and that idea's eventual undoing: they worked, the theory explaining why they worked was built around them, and the theory turned out to be wrong while the drugs kept working — the clearest demonstration that efficacy and etiological theory are independent.

The Tricyclic Antidepressants

Mechanism: effective but "dirty"

The TCAs (named for their three-ring chemical structure) block the reuptake of norepinephrine and serotonin (in varying ratios across agents), raising synaptic monoamines — the same core action the SSRIs and SNRIs later achieved selectively. But the TCAs are pharmacologically promiscuous: in addition to monoamine reuptake blockade, they potently antagonize histamine H1 (sedation, weight gain), muscarinic acetylcholine (the anticholinergic effects — dry mouth, constipation, urinary retention, blurred vision, cognitive impairment, tachycardia), and alpha-1 adrenergic (orthostatic hypotension) receptors, and — most dangerously — they block cardiac sodium channels (the source of their lethal cardiotoxicity in overdose). This broad receptor activity is why they cause so many side effects, and the SSRIs' entire reason for being was to achieve the therapeutic monoamine reuptake blockade without the H1, muscarinic, alpha-1, and sodium-channel actions that make the TCAs burdensome and dangerous. The TCA pharmacology is the "before" picture that makes the SSRIs' selectivity legible.

The agents and their gradient

The TCAs span a spectrum from more serotonergic to more noradrenergic, and from tertiary amines (more potent reuptake blockade, more side effects, more sedating) to secondary amines (cleaner, better tolerated, more noradrenergic):

• Amitriptyline and imipramine (tertiary amines) — the prototypes; potent, sedating, anticholinergic; amitriptyline heavily used (at low doses) for pain and sleep.
• Nortriptyline and desipramine (secondary amines, and the active metabolites of amitriptyline and imipramine respectively) — better tolerated, less anticholinergic, desipramine the most noradrenergic; nortriptyline is often the best-tolerated TCA and the one with therapeutic-level monitoring established.
• Clomipramine — the most serotonergic TCA, and uniquely important: it is arguably the most effective anti-obsessional agent ever studied, the TCA for OCD, displaced by SSRIs on tolerability but not clearly surpassed on efficacy.
• Doxepin — strongly antihistaminic; at very low doses, a specific hypnotic (insomnia) exploiting the H1 blockade.

What they do clinically

• Severe, melancholic, and treatment-resistant depression — where the TCAs may be more effective than SSRIs. Meta-analytic and inpatient data suggest TCAs (especially the more noradrenergic agents) outperform SSRIs in severe and melancholic depression and in hospitalized patients — a genuine efficacy advantage that justifies their use when first-line agents fail or when illness is severe.
• OCD — clomipramine, a first-line-grade treatment (with SSRIs).
• Chronic pain — a major, ongoing use: TCAs (amitriptyline, nortriptyline) are first-line for neuropathic pain, migraine prophylaxis, fibromyalgia, and other chronic pain syndromes, at doses often lower than antidepressant doses, via noradrenergic descending-inhibition and other mechanisms. This pain indication keeps TCAs in wide use long after their demotion as antidepressants.
• Other niches — low-dose doxepin for insomnia; imipramine for childhood enuresis (historically) and panic disorder; various.

The problems

The reasons for demotion, all flowing from the "dirty" pharmacology:

• Lethal in overdose — the decisive problem. TCA overdose causes fatal cardiac arrhythmias and conduction block (sodium-channel blockade) and seizures; a relatively small multiple of the therapeutic dose can kill. In a population at elevated suicide risk, prescribing a drug that is itself a lethal means is a grave liability — and this, more than anything, drove the shift to the overdose-safe SSRIs. (The contrast is stark: SSRI overdose is rarely fatal; TCA overdose is a medical emergency and a common completed-suicide method in the TCA era.)
• Anticholinergic burden — dry mouth, constipation, urinary retention, blurred vision, cognitive impairment and confusion (especially dangerous in the elderly, where TCAs are on the Beers list), tachycardia.
• Cardiac effects even at therapeutic doses — QT/conduction effects, orthostatic hypotension (alpha-1), warranting ECG monitoring and caution in cardiac disease and the elderly.
• Sedation and weight gain (H1), and the need for therapeutic drug monitoring for some agents (nortriptyline has a defined therapeutic window; imipramine/desipramine levels are used).

The honest summary: the TCAs are effective antidepressants — arguably more effective than SSRIs for severe and melancholic depression — and irreplaceable for several pain syndromes and (clomipramine) OCD, demoted to later-line antidepressant use almost entirely because they are dangerous in overdose and burdened by anticholinergic and cardiac effects, not because they don't work. For the right patient (severe/resistant depression, neuropathic pain, OCD), with attention to overdose risk and cardiac/anticholinergic safety, they remain genuinely valuable.

The Monoamine Oxidase Inhibitors

Mechanism

The MAOIs inhibit monoamine oxidase, the mitochondrial enzyme that degrades monoamine neurotransmitters, thereby raising synaptic levels of serotonin, norepinephrine, and dopamine simultaneously — a broader monoaminergic action than any other antidepressant class. Two enzyme subtypes matter:

• MAO-A metabolizes serotonin, norepinephrine, and (with MAO-B) dopamine, and — critically — metabolizes tyramine in the gut. MAO-A inhibition drives both the antidepressant effect and the dangerous tyramine interaction.
• MAO-B preferentially metabolizes dopamine and phenylethylamine; selective MAO-B inhibition (low-dose selegiline) is used in Parkinson's disease and, at antidepressant doses, loses selectivity.

The agents divide by selectivity and reversibility:

• Irreversible, non-selective (phenelzine, tranylcypromine, isocarboxazid) — the classic MAOIs; potent, effective, and carrying the full dietary and interaction burden (the enzyme is permanently inactivated, requiring ~2 weeks to regenerate — hence the long washout).
• Selective/reversible — transdermal selegiline (an MAO-B-preferring agent delivered through the skin, bypassing gut MAO-A at lower doses so that dietary restrictions are relaxed at the lowest dose — a genuine engineering solution to the tyramine problem) and moclobemide (a reversible MAO-A inhibitor, RIMA, available outside the U.S., where dietary tyramine can displace the drug from the enzyme, sharply reducing the hypertensive-crisis risk).

What they do clinically

The MAOIs are, by reputation among experts and by several lines of evidence, among the most effective antidepressants, with two particular strengths:

• Atypical depression — the depression subtype with mood reactivity, hypersomnia, hyperphagia (weight gain), leaden paralysis, and rejection sensitivity — where MAOIs have historically been considered the most effective treatment, outperforming TCAs and arguably SSRIs. This is the MAOIs' signature niche.
• Treatment-resistant depression — when multiple other agents have failed, MAOIs are a genuinely valuable option, sometimes producing response where everything else failed, precisely because their broad triple-monoamine mechanism differs from the reuptake inhibitors. The expert consensus is that MAOIs are underused in treatment-resistant depression specifically because clinicians are unfamiliar with and wary of them.

They also have roles in panic disorder, social anxiety, and other conditions.

The problems — the reason for near-abandonment

The MAOIs were driven to the margins almost entirely by their interactions, which are genuinely dangerous:

• The tyramine reaction ("cheese reaction"). Tyramine — abundant in aged, fermented, and spoiled foods (aged cheeses, cured/fermented meats, soy products, draft beer, certain wines, fermented foods) — is normally degraded by gut MAO-A. With MAO-A inhibited, dietary tyramine is absorbed, displaces stored norepinephrine, and can cause a hypertensive crisis — severe blood pressure elevation, headache, and risk of stroke. This mandates a tyramine-restricted diet, the single biggest practical burden of MAOI use and the main reason for clinician avoidance (the transdermal selegiline patch and moclobemide substantially reduce this).
• Serotonin syndrome. Combining an MAOI with serotonergic drugs (SSRIs, SNRIs, TCAs, triptans, tramadol, meperidine, dextromethorphan, linezolid, and others) can cause serotonin syndrome — autonomic instability, neuromuscular hyperactivity, altered mental status, potentially fatal. This requires a long washout when switching between an MAOI and a serotonergic drug (commonly ~2 weeks, 5 weeks after fluoxetine owing to its long half-life), and makes MAOIs awkward to combine and to switch.
• Other interactions — with sympathomimetics (stimulants, decongestants — hypertensive crisis), and others; orthostatic hypotension (common, sometimes dose-limiting), weight gain (phenelzine), insomnia/activation (tranylcypromine), and the dietary vigilance the patient must maintain.

The honest summary: the MAOIs are highly effective antidepressants — arguably the best for atypical depression and a genuine option in treatment resistance — relegated to near-obsolescence not by inefficacy but by the tyramine and serotonergic-interaction dangers and the dietary discipline they require. The result is that an effective class is unavailable to many patients who would benefit, because the expertise to use it safely has atrophied — a real loss, and one the safer formulations (selegiline patch, moclobemide) only partly remedy. In expert hands, for atypical and treatment-resistant depression, they remain a valuable and underused tool.

A Theoretical Synthesis

The TCAs and MAOIs deliver a lesson that reframes the entire history of antidepressant pharmacology: the progress from first-generation to SSRIs was progress in safety and tolerability, not in efficacy. The SSRIs do not treat depression better than the TCAs and MAOIs — by several measures (severe/melancholic depression for TCAs, atypical depression for MAOIs) the older drugs are more effective — they treat it more safely (no overdose lethality, no dietary restrictions) and more tolerably (cleaner side-effect profiles), which is what made depression a mass-treatable, primary-care, long-term-medication condition. This is a genuine and enormous achievement, but it is an achievement of deliverability, not of antidepressant power, and conflating the two — assuming the newer drugs must work better — misreads the history. The first-generation drugs are the proof that "newer" in psychiatric pharmacology has usually meant "safer and easier," not "more effective."

They also illuminate, by contrast, what selectivity bought and cost. The TCAs' broad receptor promiscuity (H1, muscarinic, alpha-1, sodium channels) caused their side effects and overdose lethality; the SSRIs' selectivity for the serotonin transporter eliminated those — but the very breadth of the old drugs may underlie some of their efficacy advantages (the noradrenergic component of TCAs in severe depression; the triple-monoamine action of MAOIs in atypical and resistant depression). The clean drugs are safer and may, in some patients, be less powerful precisely because they are clean — a trade-off that the dual-action SNRIs and the multimodal agents have since tried to renegotiate. The "dirty" pharmacology was a liability and, possibly, part of the potency.

And they exemplify the series-wide theme of effective drugs marginalized by non-efficacy factors — overdose safety, interaction burden, prescribing convenience, and the atrophy of clinical expertise — which, alongside lithium and clozapine, makes the same point: what patients actually receive is shaped as much by tolerability, safety, marketing, and clinician familiarity as by efficacy, and the most effective option is frequently not the one prescribed. The corrective is not to return to routine first-generation use (their dangers are real and justified their demotion) but to remember that they exist, retain the expertise to use them, and reach for them when the safer drugs fail — which, given that a third or more of depressed patients do not durably remit on first-line treatment, is far more often than current practice reflects.

The Clinical Bottom Line

Tricyclic antidepressants remain genuinely valuable, demoted on safety not efficacy:

• Severe, melancholic, and treatment-resistant depression — where TCAs may outperform SSRIs, a real later-line (and sometimes earlier) option with attention to overdose risk (limited quantities in suicidal patients), cardiac status (ECG, caution in cardiac disease and the elderly), and anticholinergic burden.
• Clomipramine for OCD — a first-line-grade anti-obsessional agent.
• Chronic and neuropathic pain, migraine prophylaxis, fibromyalgia (amitriptyline, nortriptyline, often low-dose) — a major ongoing use independent of their antidepressant role.
• Low-dose doxepin for insomnia.
• Favor the better-tolerated secondary amines (nortriptyline, desipramine) when using as antidepressants; respect overdose lethality in at-risk patients.

MAOIs are highly effective and underused, relegated by interaction burden not inefficacy:

• Atypical depression — historically the most effective treatment.
• Treatment-resistant depression — a genuine option when other classes fail, underused mainly because clinicians are unfamiliar with them.
• Require tyramine-restricted diet, careful avoidance of serotonergic and sympathomimetic drugs, and washout periods when switching; the transdermal selegiline patch and moclobemide substantially reduce the dietary/interaction burden and are reasonable ways to access the class more safely.

Across both classes: these first-generation drugs were superseded on safety and tolerability, not efficacy — by several measures they are equal or superior antidepressants — and a careful psychiatry keeps them available, retains the expertise to use them safely, and reaches for them when the safer first-line agents fail. Their near-abandonment is, like lithium's and clozapine's neglect, a case of an effective treatment lost to non-efficacy factors, and remembering they exist is part of competent care for the patients the newer drugs do not help.

Selected References and Further Reading

1. Kuhn, R. (1958). The treatment of depressive states with G 22355 (imipramine hydrochloride). American Journal of Psychiatry, 115(5), 459–464.
2. López-Muñoz, F., & Alamo, C. (2009). Monoaminergic neurotransmission: The history of the discovery of antidepressants from 1950s until today. Current Pharmaceutical Design, 15(14), 1563–1586.
3. Anderson, I.M. (2000). Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability. Journal of Affective Disorders, 58(1), 19–36.
4. Barbui, C., & Hotopf, M. (2001). Amitriptyline v. the rest: Still the leading antidepressant after 40 years of randomised controlled trials. British Journal of Psychiatry, 178, 129–144.
5. Cipriani, A., et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs. The Lancet, 391(10128), 1357–1366.
6. Gillman, P.K. (2007). Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. British Journal of Pharmacology, 151(6), 737–748.
7. Saarto, T., & Wiffen, P.J. (2007). Antidepressants for neuropathic pain. Cochrane Database of Systematic Reviews, Issue 4, CD005454.
8. Clomipramine Collaborative Study Group (1991). Clomipramine in the treatment of patients with obsessive-compulsive disorder. Archives of General Psychiatry, 48(8), 730–738.
9. Kerr, G.W., McGuffie, A.C., & Wilkie, S. (2001). Tricyclic antidepressant overdose: A review. Emergency Medicine Journal, 18(4), 236–241.
10. Fiedorowicz, J.G., & Swartz, K.L. (2004). The role of monoamine oxidase inhibitors in current psychiatric practice. Journal of Psychiatric Practice, 10(4), 239–248.
11. Thase, M.E., Trivedi, M.H., & Rush, A.J. (1995). MAOIs in the contemporary treatment of depression. Neuropsychopharmacology, 12(3), 185–219.
12. Liebowitz, M.R., et al. (1988). Antidepressant specificity in atypical depression (phenelzine vs imipramine). Archives of General Psychiatry, 45(2), 129–137.
13. Stewart, J.W., et al. (and the atypical-depression / MAOI literature, Columbia group). Archives of General Psychiatry.
14. Robinson, D.S., & Amsterdam, J.D. (2008). The selegiline transdermal system in major depressive disorder. Journal of Affective Disorders, 105(1–3), 15–23.
15. Lotufo-Neto, F., Trivedi, M., & Thase, M.E. (1999). Meta-analysis of the reversible inhibitors of monoamine oxidase type A (moclobemide and brofaromine) for depression. Neuropsychopharmacology, 20(3), 226–247.
16. Gillman, P.K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434–441.
17. Shulman, K.I., Herrmann, N., & Walker, S.E. (2013). Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs, 27(10), 789–797.
18. Undurraga, J., & Baldessarini, R.J. (2012). Randomized, placebo-controlled trials of antidepressants for acute major depression: Thirty-year meta-analytic review. Neuropsychopharmacology, 37(4), 851–864.
19. Perry, P.J. (1996). Pharmacotherapy for major depression with melancholic features: Relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. Journal of Affective Disorders, 39(1), 1–6.
20. Baldessarini, R.J. (2013). Chemotherapy in Psychiatry (3rd ed.). Springer.